{"id":9984,"date":"2025-12-02T06:52:01","date_gmt":"2025-12-02T12:52:01","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9984"},"modified":"2026-01-05T06:40:46","modified_gmt":"2026-01-05T12:40:46","slug":"nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/","title":{"rendered":"La terapia optogen\u00e9tica MCO-010 de Nanoscope Therapeutics se presenta en el Congreso FLORetina-ICOOR 2025."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>,\u00a02 de diciembre de 2025<\/span>\u00a0 \u2014 NanoscopeTherapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy que el Dr. Jordi Mon\u00e9s y el Dr. Allen C. Ho presentar\u00e1n los resultados del estudio RESTORE de fase 2b\/3 y del estudio REMAIN de seguimiento a largo plazo en el\u00a0Congreso FLOretina-ICOOR 2025<\/a>, 4 de diciembreth<\/sup>-7th<\/sup>\u00a0En la Fortezza da Basso de Florencia, Italia, las presentaciones resaltan los resultados positivos de eficacia y seguridad a 3 a\u00f1os demostrados por la terapia optogen\u00e9tica patentada de Nanoscope, MCO-010, mediante una \u00fanica inyecci\u00f3n intrav\u00edtrea en pacientes con p\u00e9rdida grave de visi\u00f3n por retinosis pigmentaria (RP).<\/p>

\u201cComo demuestran estos estudios, lograr una mejor\u00eda visual constante de tres l\u00edneas durante m\u00e1s de tres a\u00f1os con una sola dosis de MCO-010 es un resultado extraordinario para pacientes con visi\u00f3n grave debido a retinosis pigmentaria\u201d, afirm\u00f3 el Dr. Jordi Mon\u00e9s, director del Institut de la Macula y de la Fundaci\u00f3n Barcelona Macula. \u201cMe complace compartir estos resultados, as\u00ed como el s\u00f3lido perfil de seguridad de MCO-010, en el Congreso Anual FLORetina-ICCOR, que contar\u00e1 con la presencia de algunos de los principales expertos mundiales en el tratamiento de enfermedades vitreorretinianas\u201d.\u201d<\/p>

Los detalles de las presentaciones son los siguientes:<\/p>

T\u00edtulo:<\/b>\u00a0REMAIN: Seguimiento a largo plazo de 3 a\u00f1os del estudio RESTORE que eval\u00faa la eficacia y la seguridad de la terapia optogen\u00e9tica MCO-010 en la retinosis pigmentaria avanzada.
Presentador:<\/b>\u00a0Jordi Mon\u00e9s, MD, PhD, Director del Institut de la M\u00e0cula y Barcelona Macula Foundation (Espa\u00f1a)<\/a>
Fecha \/ Hora:<\/b>\u00a0Viernes, 5 de diciembre | 9:18 CET
Sesi\u00f3n:<\/b>\u00a0Documentos gratuitos destacados 2
Ubicaci\u00f3n:<\/b>\u00a0Sala Del Carmine<\/p>

T\u00edtulo:<\/b>\u00a0Eficacia y seguridad longitudinales de la terapia optogen\u00e9tica MCO-010 para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a retinosis pigmentaria.
Presentador:<\/b>\u00a0Allen C. Ho, MD, Director de Investigaci\u00f3n de Retina, Wills Eye Hospital; Asesor M\u00e9dico Jefe, Nanoscope Therapeutics<\/a>
Fecha \/ Hora:<\/b>\u00a0S\u00e1bado, 6 de diciembre | 11:18 CET
Sesi\u00f3n:<\/b>\u00a0Retina Futura: Enfoque en las terapias emergentes para las enfermedades retinianas hereditarias
Ubicaci\u00f3n:<\/b>\u00a0Sala Santa Croce<\/p>

La FDA de EE. UU. ha otorgado a MCO-010 la designaci\u00f3n de V\u00eda R\u00e1pida y de Medicamento Hu\u00e9rfano, y actualmente se encuentra en tr\u00e1mite una Solicitud de Licencia para Productos Biol\u00f3gicos (BLA) para la retinosis pigmentaria. La Agencia Europea de Medicamentos ha otorgado a MCO-010 cinco designaciones de Medicamento Hu\u00e9rfano para un amplio espectro de degeneraciones retinianas que implican la p\u00e9rdida de fotorreceptores.<\/p>

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de medicamento hu\u00e9rfano de la EMA para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience a finales de 2025. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>

Contacto:
<\/b>Terap\u00e9utica del nanoscopio
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Dec. 2, 2025\u00a0 \u2014 NanoscopeTherapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Dr. Jordi Mon\u00e9s and Dr. Allen C. Ho will present Phase 2b\/3 RESTORE and Long-Term-Follow-Up REMAIN study results at the\u00a0FLORetina-ICOOR 2025 Congress, December […]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics' MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics' MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T12:52:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T12:40:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics’ MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress\",\"datePublished\":\"2025-12-02T12:52:01+00:00\",\"dateModified\":\"2026-01-05T12:40:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/\"},\"wordCount\":610,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/\",\"name\":\"Nanoscope Therapeutics' MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-12-02T12:52:01+00:00\",\"dateModified\":\"2026-01-05T12:40:46+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/12\\\/02\\\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics’ MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La terapia optogen\u00e9tica MCO-010 de Nanoscope Therapeutics se presenta en el Congreso FLORetina-ICOOR 2025 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics' MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-12-02T12:52:01+00:00","article_modified_time":"2026-01-05T12:40:46+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics’ MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress","datePublished":"2025-12-02T12:52:01+00:00","dateModified":"2026-01-05T12:40:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/"},"wordCount":610,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/","url":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/","name":"La terapia optogen\u00e9tica MCO-010 de Nanoscope Therapeutics se presenta en el Congreso FLORetina-ICOOR 2025 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-12-02T12:52:01+00:00","dateModified":"2026-01-05T12:40:46+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/12\/02\/nanoscope-therapeutics-mco-010-optogenetic-therapy-featured-at-floretina-icoor-2025-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics’ MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=9984"}],"version-history":[{"count":9,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9984\/revisions"}],"predecessor-version":[{"id":9993,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/9984\/revisions\/9993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=9984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=9984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=9984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}